Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: A study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone

Gynecologic Oncology

Volumn 91, Issue 3, 2003, Pages 526-533

  Vereide, A B ^a   Arnes, M ^a   Straume, B ^a   Maltau, J M ^a   Orbo A ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE;

ADULT; AGED; ARTICLE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; DISEASE COURSE; DRUG EFFECT; DRUG MEGADOSE; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; EVALUATION; FEMALE; HUMAN; MICROSCOPY; MORPHOMETRICS; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RISK ASSESSMENT; SAMPLE; SCORING SYSTEM; STEREOLOGY; TISSUE; WORLD HEALTH ORGANIZATION;

ADULT; CELL NUCLEUS; ENDOMETRIAL HYPERPLASIA; FEMALE; HUMANS; INTRAUTERINE DEVICES; LEVONORGESTREL; MEDROXYPROGESTERONE; MIDDLE AGED;

EID: 1642417350     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.07.002     Document Type: Article

References (29)

1. Gal D. Hormonal therapy for lesions of the endometrium. Semin oncol. 13:1986;33-36.
2. Ferenczy A., Gelfand M. The biologic significance of cytological atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol. 160:1989;126-131.
3. Lindahl B., Alm P., Femo M., Norgren A. Endometrial hyperplasia a prospective randomized study of histopathology, tissue steroid receptors and plasma steroids after abrasio, with or without high dose gestagen treatment. Anticancer Res. 10:1990;725-730.
4. Lindahl B., Willen R. Endometrial hyperplasia. Clinico-pathological considerations of a prospective randomised study after abrasio only or high-dose gestagen treatment. Results of 2 years follow-up of 292 patients. Anticancer Res. 11:1991;403-406.
5. Tropé C., Lindahl B. Premalignant lesions of the endometrium clinical features and management. Coppleson M. Gynecologic oncology. 2nd ed:1992;747-751 Churchill Livingstone, New York.
6. Randall T.C., Kurman R.J. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. 90:1997;434-440.
7. Andersson J.K., Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol. 97:1990;690-694.
8. Barrington J.W., Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol. 104:1997;614-616.
9. Nilsson C.G., Haukkamaa M., Vierola H., Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol. 17:1982;529-536.
10. Perino A., Quartararo P., Catinella E., Genova G., Cittadini E. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur Fertil. 18:1987;137-140.
11. Scarselli G., Tantini C., Colafranceschi M., et al. Levo-norgestrel-nova- T and precancerous lesions of the endometrium. Eur J. Gynaecol Oncol. 9:1988;284-286.
12. Rose G.L., Edmonds D.K. Levonorgestrel IUS - treatment for endometrial cystic hyperplasia. Gynecology case reports. 104:1997;614-616.
13. Baak J.P., Nauta J.J., Wisse-Brekelmans E.C., Bezemer P.D. Architectural and nuclear morphometrical features together are more important prognosticators in endometrial hyperplasia than nuclear morphometrical features alone. J. Pathol. 154:1988;335-341.
14. Baak J.P.A., Ørbo A., Diest P.J. Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasia. Am J Surg Path. 25:2001;930-935.
15. Kurman R.J., Kaminski P.F., Norris H.J. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 56:1985;403-412.
16. Dietel M. The histological diagnosis of endometrial hyperplasia is there a need to simplify? Virchows Arch. 439:2001;604-608.
17. Kendall B.S., Ronnett B.M., Isacson C., et al. Reproducibility of the diagnosis of endometrial hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol. 2:1998;1012-1019.
18. Bergeron C., Nogales F.F., Masseroli M., et al. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol. 23:1999;1102-1108.
19. Baak JPA, Oort J. The case for quantitative pathology in cancer diagnosis and treatment. In: Manual of quantitative pathology in cancer diagnosis and prognosis. Heidelberg/New York: Springer; 1991, p. 7-18.
20. Baak J.P., Ladekarl M., Sørensen F.B. Reproducibility of mean nuclear volume and correlation with mean nuclear area in breast cancer. Hum Pathol. 25:1994;80-85.
21. Dunton C.J., Baak J.P., Palazzo J.P., van Diest P.J., McHugh M., Widra E.A. Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer. Am J Obstet Gynecol. 174:1996;1518-1521.
22. Ørbo A., Baak J.P., Kleivan I., et al. Computerized morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long term retrospective study from northern Norway. J Clin Pathol. 53:2000;697-703.
23. Mutter G.L., Baak J.P., Crum C.P., Richart R.M., Ferenczy A., Faquin W.C. Endometrial precancer diagnosis by histopathology, clonal analysis and computerized orphometry. J Pathol. 190:2000;462-469.
24. Baak J.P., Broeckaert M.A.M., van Diest P.J., et al. Prospective multicenter long-term evaluation of the computerized morphometric D-score to predict the outcome of endometrial hyperplasias. Gynecol Oncol. 76:2000;287-290.
25. Bozdogan O., Atasoy P., Erekul S., Bozdogan N., Bayram M. Apoptosis-related proteins and steroid hormone receptors in normal, hyperplastic, and neoplastic endometrium. Int J Gynecol Pathol. 21:2002;375-382.
26. Err J.F.R., Wyllie A.H., Currie A.R. Apoptosis a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 26:1972;239-257.
27. Amescua C.A., Lu J.J., Felix J.C., Stanczyk F.Z., Zheng W. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia. Gynecol Oncol. 79:2000;169-176.
28. Maruo T., Laoag-Fernandez J.B., Pakarinen P., Murakoshi H., Spitz I.M., Johansson E. Effect of levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium. Hum Reprod. 16:2001;2103-2108.
29. Hagenfeldt K., Landgren B., Edstrøm K., Johannisson E. Biochemical and morphological changes in the human endometrium induced by the progestasert device. Contraception. 16:1977;183-197.